Fresh Equities
ASX:AHZ

ASX:AHZ

Admedus Limited

4W AVG VOLUME
569.24k
Data provided by Weblink | as of close 2020-01-28
4W AVG TURNOVER
$65.12k

Admedus Limited has not announced any current capital raises, but we are collecting interest for future raises.

Demand Registered for Next Raise
< $50k
Investors Interested in Next Raise
< 10
How Fresh Equities Works
Authentication

1. Create Account

Complete your onboarding digitally in less than 3 minutes.

Authentication

2. View Terms

View the full term sheet for the capital raise.

Authentication

3. Bid for Allocation

Submit and track your bid online.

Capital Raise History

Fresh Equities does not have Admedus Limited capital raise history data.


Company Overview

Admedus is a medical technologies company delivering clinically superior solutions to help healthcare professionals to create life-changing outcomes for patients. The Company focuses on commercializing tissue engineering technology for use in cardiovascular and soft tissue repair surgery. AHZ Operates in four segments: Medical products and devices, Bio Implant operations, Regenerative medicine R&D and Immunotherapies R&D.

Type

Listed Company

GICS Sub-industry

Health Care Supplies

Head Office

Riverfront, Level 9/301 Coronation Dr, Milton QLD 4064, Australia

Health Care Supplies
Health Care
Biotech & Health

Price Chart


Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.

Loading...


Directors

Wayne Paterson

President and CEO

Dr Yanheng Wu

Non-Executive Director

John Seaberg

Chairman

Stephen Denaro

Non-Executive Director and Company Secretary

Wenyi Gu

Non Executive Director

Lishan Zhang

Non-Executive Director


Announcements

All
All Time
    Notice of Extraordinary General Meeting/Proxy Form on 24 January 2020

    Notice Of Meeting

  • SAVR Clinical Trial on 22 January 2020

    Progress Report

  • Appendix 3B on 13 January 2020

    Issued Capital

    Appendix 3B on 11 December 2019

    Issued Capital

  • Update to LeMaitre Vascular deal on 8 December 2019

    Progress Report

  • Appendix 3B on 26 November 2019

    Issued Capital

  • Response to ASX Price and Volume Query on 19 November 2019

    ASX Query

  • ADAPT Carve Out Financial Statements on 30 October 2019

    Periodic Reports

  • Appendix 4C - quarterly on 30 October 2019

    Commitments test entity quarterly reports

  • CardioCel and VascuCel LeMaitre deal clarification on 14 October 2019

    Periodic Reports

    Load More

News

Loading...